Sign Up
Stories
ADMA Biologics CFO Transition Announcement
Share
ADMA Biologics CFO Transition Revealed
ADOCIA Files 2023 Registration Document
Adial Pharmaceuticals Boosts AD04 Develo...
Adex Mining Secures $1M Loan
Adial Pharmaceuticals Raises Capital for...
FDA Warning: Cardinal's Syringe Issues
Overview
API
ADMA Biologics, Inc. revealed the CFO transition of Brian Lenz to a consulting role, with Adam Grossman taking on the Interim CFO position until a permanent replacement is appointed. The company specializes in producing biologics for immunodeficient and high-infection risk patients.
Ask a question
How might this CFO transition impact ADMA Biologics' financial strategies and future directions?
In what ways could this transition influence investor confidence in ADMA Biologics and the healthcare sector at large?
What qualities will the company seek in the new permanent CFO to maintain its focus on specialty biologics?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Nov 2023
Dec 2023
Jan 2024
Coverage